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Abstract
Background: Evidence suggests that high-level physical activity may potentially reduce cancer mortality through its immune
enhancement effect. We therefore hypothesized that survival benefits associated with physical activity might be stronger in
colorectal carcinomas with lower immune reaction at diagnosis.
Methods: Using molecular pathological epidemiology databases of 470 colon and rectal carcinoma cases in the Nurses’ Health
Study and the Health Professionals Follow-up Study, we assessed the prognostic association of postdiagnosis physical activ-
ity in strata of densities of CD3þ cells, CD8þ cells, CD45RO (PTPRC)þ cells, or FOXP3þ cells in tumor tissue. Cox proportional
hazards regression model was used to adjust for potential confounders, including microsatellite instability, CpG island meth-
ylator phenotype, long interspersed nucleotide element-1 methylation, KRAS, BRAF, and PIK3CA mutations, and expression of
CTNNB1 (beta-catenin), PTGS2 (cyclooxygenase-2), and IRS1.
Results: The association of postdiagnosis physical activity with colorectal cancer-specific mortality differed by CD3þ cell den-
sity (Pinteraction < .001). Multivariable-adjusted colorectal cancer-specific mortality hazard ratios for a quartile-unit increase in
physical activity were 0.56 (95% confidence interval ¼ 0.38 to 0.83) among cases with the lowest quartile of CD3þ cell density
compared with 1.14 (95% confidence interval ¼ 0.79 to 1.65) in cases with the highest quartile. We observed no differential
survival association of physical activity by densities of CD8þ cells, CD45ROþ cells, or FOXP3þ cells.
Conclusions: The association between postdiagnosis physical activity and colorectal cancer survival appeared stronger for
carcinomas with lower T cell infiltrates, suggesting an interactive effect of exercise and immunity on colorectal cancer
progression.
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Innate and adaptive immunity play crucial roles in suppress-
ing tumor progression (1,2). In colorectal carcinomas, high-
level infiltrates of CD3þ cells, CD8þ cells, and CD45RO
(PTPRC)þ cells in the tumor microenvironment have been as-
sociated with longer patient survival (3–7). Emerging evidence
indicates that immunotherapies targeting immune check-
point molecules such as PDCD1 (programmed cell death 1, PD-
1) and CD274 (PDCD1 ligand 1, PD-L1) can be effective in treat-
ing several cancer types (8), including colorectal cancer with
high-level microsatellite instability (MSI) (9,10). Elucidating
the interplay between tumor cells and the immune system is
of considerable importance to further improve the efficacy of
immunoprevention and immunotherapy strategies for cancer
(11–17).
High-level physical activity has been associated with lower
incidence and mortality of colorectal cancer (18–28). Evidence
suggests that physical activity may prolong colorectal cancer
patient survival through decreasing chronic inflammation in
the tumor microenvironment and enhancing the T cell-
mediated antitumor immune response (29–32). Colorectal can-
cer consists of a heterogeneous group of neoplasms due to com-
plex interactions with environmental factors, host immune
cells, and transformed cells (1,33). We considered that tumors
that had progressed despite the presence of higher T cell reac-
tion might have developed mechanisms to escape immune sur-
veillance; such tumors with higher immune reaction might
exhibit refractoriness to immunomodulatory effects of physical
activity after cancer diagnosis. We therefore hypothesized that
survival benefits associated with increased physical activity lev-
els might be stronger for tumors with lower T cell reaction than
for tumors with a higher reaction.
To test our hypothesis, we used a molecular pathological ep-
idemiology database derived from two large prospective cohort
studies in the United States with data on physical activity levels
after colorectal cancer diagnosis, tumor molecular and immune
features, and survival outcomes. We examined the interactive
prognostic association of postdiagnosis physical activity levels
and tumor-infiltrating T cells.
Methods
Study Population
We examined data from two large prospective cohort studies in
the United States: the Nurses’ Health Study (NHS, 121 701
women ages 30–55 years followed since 1976) and the Health
Professionals Follow-up Study (HPFS, 51 529 men ages 40 to
75 years followed since 1986) (34). Study participants have been
sent follow-up questionnaires biennially to update information
on demographics, lifestyle factors, and medical history and to
report newly diagnosed diseases including colorectal cancer.
The follow-up rate has been more than 90% for each question-
naire cycle in both cohorts. The National Death Index was used
to ascertain deaths of study participants and identify patients
with unreported lethal colorectal cancer. Informed consent was
obtained from all participants at study enrollment. This study
was approved by the Human Subjects Committees at Harvard
T.H. Chan School of Public Health and Brigham and Women’s
Hospital (Boston, MA).
We included 470 colorectal cancer cases with available data
on postdiagnosis physical activity levels and T cell densities in
tumor tissue among participants diagnosed with colorectal
cancer through 2008. We included both colon and rectal carci-
noma cases based on the colorectal continuum model (35).
Patients were followed until death or end of follow-up (June 30,
2014 for the NHS; January 1, 2014 for the HPFS), whichever came
first. Study physicians, blinded to exposure data, reviewed med-
ical records of patients diagnosed with colorectal cancer to col-
lect data on tumor characteristics and to identify causes of
death for deceased patients. We collected formalin-fixed paraf-
fin-embedded tumor tissue samples from hospitals throughout
the United States where participants with colorectal carcinoma
underwent tumor resection. A single pathologist (SO), blinded
to other data, conducted a central review of hematoxylin and
eosin-stained tissue sections of all colorectal carcinoma cases
and collected data on histopathological characteristics, includ-
ing tumor differentiation and four lymphocytic reaction pat-
terns (Crohn-like lymphoid reaction, peritumoral lymphocytic
reaction, intratumoral periglandular reaction, and tumor-
infiltrating lymphocytes) (36).
Assessment of Physical Activity Levels
In the NHS and HPFS, leisure-time physical activity has been
assessed biennially since 1986 using a self-administered phys-
ical activity questionnaire, which was validated against physi-
cal activity diaries in which the participants documented the
duration of time spent in activities as previously described
(37). Participants reported the duration of physical activity for
each component of physical activity. Based on this informa-
tion, we calculated a metabolic equivalent task score (METS)
(38), which was defined as the ratio of the metabolic rate of
specific activities to the resting metabolic rate (39,40). We
summed up the METS for each activity to obtain the total
METS-hours/week. To avoid the period of active anti-cancer
treatment, we used questionnaire data reported between 6
and 48 months after diagnosis of colorectal cancer. To mini-
mize the bias arising from reduced physical activity due to the
progression of disease, physical activity was evaluated at the
earliest time period after the diagnosis of colorectal cancer.
Taking into account sex differences in lifestyle and physical
activity, we classified physical activity levels into sex-specific
quartiles (39,40).
Immunohistochemistry
We constructed tissue microarrays from colorectal cancer tis-
sue blocks (41) and conducted immunohistochemistry for
CD3, CD8, CD45RO, and FOXP3, as previously described (7). We
used an automated scanning microscope and the Ariol image
analysis system (Genetix, CA) to measure T cell densities
(cells/mm2) in tumor tissue. We assessed up to four tissue mi-
croarray cores from each tumor and calculated the average
density of each tumor-infiltrating T cell subset. If applicable,
we categorized T cell densities into low vs high by the median
value.
Immunohistochemical analyses for CTNNB1 (beta-catenin)
expression (42), PTGS2 (cyclooxygenase-2) expression (39), and
IRS1 expression (40) were performed using a mouse anti-
CTNNB1 antibody (BD Transduction Laboratories, CA), anti-
PTGS2 antibody (Cayman Chemical, MI), and anti-IRS1 antibody
(Millipore, Billerica, MA), respectively.
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Analyses of Microsatellite Instability, DNA Methylation,
and KRAS, BRAF, and PIK3CAMutations
DNA was extracted from archival formalin-fixed, paraffin-
embedded tumor tissue. We determined MSI status using 10 mi-
crosatellite markers (D2S123, D5S346, D17S250, BAT25, BAT26,
BAT40, D18S55, D18S56, D18S67, and D18S487), as previously de-
scribed (43). We defined MSI-high as the presence of instability
in 30% or more of the markers, and non-MSI-high as instability
in less than 30% of the markers. Using bisulfite-treated DNA, we
quantified DNA methylation in eight CpG island methylator
phenotype (CIMP)-specific promoters (CACNA1G, CDKN2A,
CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1) and in long
interspersed nucleotide element-1 (LINE-1) (44,45). We defined
CIMP-high as the presence of six or more methylated promoters
and CIMP-low/negative as five or fewer methylated promoters
(45). We conducted polymerase chain reaction and pyrose-
quencing targeted for KRAS (codons 12, 13, 61, and 146) (46),
BRAF (codon 600) (43), and PIK3CA (exons 9 and 20) (47).
Statistical Analysis
Detailed information on statistical methods is included in
Supplementary Methods (available online). All statistical analy-
ses were performed using SAS software (version 9.4, SAS
Institute, Cary, NC), and all P values were two-sided. Our primary
hypothesis testing was assessment of a statistical interaction
(using the Wald test on the cross-product) between postdiagno-
sis physical activity levels (the median value of each decile cate-
gory) and T cell densities in tumor tissue (the median value of
each decile category) in the Cox proportional hazards regression
model for colorectal cancer-specific mortality analysis. Variables
for physical activity and T cell densities were treated as decile
categorical variables to reduce the influential effect of a few arbi-
trary cutoff points. In our primary hypothesis testing on new
discoveries, we used the a level of 0.005 (48). All other analyses
including evaluations of stratum-specific hazard ratios (HRs)
and survival curves represented secondary analyses. In our sec-
ondary and other exploratory analyses, we recognized multiple
comparisons associated with those analyses and used the a level
of 0.005. Outcome endpoints were colorectal cancer-specific
mortality and overall mortality. Survival time was defined as the
time since colorectal cancer diagnosis to death or the end of
follow-up, whichever came first, and was left-truncated at the
time of the first postdiagnosis questionnaire return.
To reduce bias due to the availability of postdiagnosis ques-
tionnaire data, the inverse probability weighting (IPW) method
was used in all survival analyses (49–51). We estimated the
probability of questionnaire return after colorectal cancer diag-
nosis using the multivariable logistic regression model as previ-
ously described (49) and used the inverse probability to weight
each patient. When we performed sex-stratified IPW-adjusted
Cox regression analyses without truncation of weight, the
results remained consistent (data not shown). Multivariable
sex-stratified Cox proportional hazards models initially in-
cluded age at diagnosis, year of diagnosis, prediagnosis physical
activity, postdiagnosis body mass index, history of colorectal
cancer in any first-degree relatives, tumor location, tumor dif-
ferentiation, disease stage, MSI status, CIMP, LINE-1 methyla-
tion level, BRAF mutation, KRAS mutation, PIK3CA mutation,
nuclear CTNNB1 expression, PTGS2 expression, and IRS1 ex-
pression. A backward elimination was performed with a thresh-
old of P equals .05 to select variables for the final models. We
also estimated HRs for a quartile-unit increase of postdiagnosis
physical activity levels in strata of levels of T cell densities using
a re-parameterization of the interaction term in a single regres-
sion model (45). The cases with missing data were included in
the majority category of a given categorical covariate to limit
the degrees of freedom of the models. For cases with missing
data on LINE-1 methylation level (2.1%) and IRS1 expression
(12.0%), we assigned a separate indicator variable for each vari-
able. We confirmed that excluding cases with missing informa-
tion in any of the covariates did not alter our results
substantially (data not shown). The proportionality of hazards
assumption was evaluated using a time-dependent variable,
which was the cross-product of the postdiagnosis physical ac-
tivity variable and survival time (P > .05). Results of Cox regres-
sion analyses without IPW, which were similar to those with
IPW, are shown in Supplementary Table 1 (available online).
Survival probabilities were estimated using the IPW-adjusted
Kaplan-Meier method and compared using the weighted log-
rank test (52).
Results
We included 470 colorectal cancer cases with available data on
postdiagnosis physical activity levels and T cell densities in tu-
mor tissue. Table 1 summarizes the clinical, pathological, and
molecular characteristics of colorectal cancer cases according to
quartiles of postdiagnosis physical activity levels. During the
median follow-up time of 17.3 years (interquartile range ¼ 14.9
to 20.6 years) for all censored cases, there were 275 deaths from
any cause, including 100 colorectal cancer-specific deaths.
Postdiagnosis physical activity levels were associated with colo-
rectal cancer-specific mortality overall (Table 2).
In our primary hypothesis testing, the association of post-
diagnosis physical activity levels and colorectal cancer-specific
mortality differed by CD3þ cell density (Pinteraction < .001; with
the a level of 0.005; Table 2 and Supplementary Table 2, avail-
able online). The multivariable-adjusted HRs of colorectal
cancer-specific mortality for a quartile-unit increase in post-
diagnosis physical activity levels were 0.56 (95% confidence in-
terval [CI] ¼ 0.38 to 0.83) in the lowest quartile of CD3þ cell
density and 1.14 (95% CI ¼ 0.79 to 1.65) in the highest quartile of
CD3þ cell density. The differential prognostic association was
similarly observed in women and men, although statistical
power was limited in each subgroup (Table 3). Figure 1 shows
IPW-adjusted Kaplan-Meier survival curves of colorectal cancer-
specific survival according to tertiles of postdiagnosis physical
activity levels, and Table 4 shows HRs of cancer-specific mortal-
ity in each category of postdiagnosis physical activity levels.
Taking into account the small number of events in each cate-
gory, we used tertiles of postdiagnosis physical activity levels
for these analyses. Considering the influence of arbitrary cutoff
points, we entered postdiagnosis physical activity levels as a
continuous variable into the models and obtained similar
results (Supplementary Table 3, available online). When we ex-
cluded stage IV patients (Supplementary Table 4, available on-
line) or patients who died within 6 months of the first
postdiagnosis questionnaire return (n¼ 12, data not shown), we
observed a similar interactive prognostic association of post-
diagnosis physical activity levels and CD3þ cell density
(Pinteraction < .001). We did not observe any statistically signifi-
cant interaction of postdiagnosis physical activity levels with
densities of CD8þ cells, CD45ROþ cells, or FOXP3þ cells
(Pinteraction > .13; Table 2).
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Table 1. Clinical, pathological, and molecular characteristics of colorectal cancer cases according to postdiagnosis physical activity levels
Postdiagnosis physical activity levels
Quartile 1 Quartile 2 Quartile 3 Quartile 4
All cases (Lowest) (Highest)
Characteristic* (n ¼ 470) (n ¼ 114) (n ¼ 121) (n ¼ 117) (n ¼ 118)
Postdiagnosis physical activity levels (METS-h/wk), median (range)
Female (n ¼ 252, NHS) 7.3 (0–157.9) 0.7 (0–2.2) 3.7 (2.3–7.2) 10.2 (7.3–16.9) 36.0 (17.0–157.9)
Male (n ¼ 218, HPFS) 15.4 (0–155.9) 1.0 (0–4.9) 8.6 (5.0–15.3) 23.0 (15.4–34.9) 57.3 (35.0–155.9)
Mean age 6 SD, y 67.8 6 8.0 69.4 6 8.7 68.36 7.9 67.0 6 8.0 66.5 6 7.2
Year of diagnosis
1995 or before 209 (44%) 41 (36%) 61 (50%) 50 (43%) 57 (48%)
1996 to 2000 194 (41%) 56 (49%) 45 (37%) 47 (40%) 46 (39%)
2001 to 2008 67 (14%) 17 (15%) 15 (12%) 20 (17%) 15 (13%)
Family history of colorectal cancer in first-degree relative(s)
Absent 369 (79%) 89 (78%) 89 (74%) 100 (85%) 91 (77%)
Present 101 (21%) 25 (22%) 32 (26%) 17 (15%) 27 (23%)
Body mass index
<25 kg/m2 209 (48%) 41 (41%) 55 (48%) 58 (53%) 55 (51%)
25 to 29.9 kg/m2 156 (36%) 35 (35%) 42 (37%) 37 (34%) 42 (39%)
30 kg/m2 68 (16%) 25 (25%) 17 (15%) 15 (14%) 11 (10%)
Tumor location
Cecum 89 (19%) 27 (24%) 21 (17%) 19 (16%) 22 (19%)
Ascending to transverse colon 139 (30%) 29 (25%) 34 (28%) 42 (36%) 34 (29%)
Descending to sigmoid colon 144 (31%) 29 (25%) 44 (36%) 35 (30%) 36 (31%)
Rectum 97 (21%) 29 (25%) 22 (18%) 20 (17%) 26 (22%)
Tumor differentiation
Well to moderate 431 (92%) 109 (96%) 106 (88%) 107 (92%) 109 (93%)
Poor 37 (7.9%) 5 (4.4%) 15 (12%) 9 (7.8%) 8 (6.8%)
AJCC disease stage
I 115 (26%) 29 (27%) 21 (19%) 36 (33%) 29 (26%)
II 158 (36%) 29 (27%) 44 (40%) 38 (35%) 47 (42%)
III 138 (31%) 38 (35%) 37 (34%) 31 (28%) 32 (29%)
IV 29 (6.6%) 13 (12%) 8 (7.3%) 5 (4.6%) 3 (2.7%)
MSI status
Non-MSI-high 386 (83%) 92 (81%) 96 (81%) 99 (85%) 99 (84%)
MSI-high 81 (17%) 22 (19%) 23 (19%) 17 (15%) 19 (16%)
CIMP status
Low/negative 384 (82%) 87 (78%) 99 (83%) 101 (86%) 97 (83%)
High 82 (18%) 25 (22%) 21 (18%) 16 (14%) 20 (17%)
Mean LINE-1 methylation level 6 SD (%) 61.1 6 9.6 60.5 6 10.0 60.46 9.3 60.8 6 10.1 62.9 6 9.0
KRAS mutation
Wild-type 269 (58%) 64 (56%) 65 (55%) 72 (63%) 68 (58%)
Mutant 195 (42%) 50 (44%) 53 (45%) 43 (37%) 49 (42%)
BRAF mutation
Wild-type 400 (86%) 96 (85%) 105 (88%) 100 (88%) 99 (85%)
Mutant 64 (14%) 17 (15%) 15 (13%) 14 (12%) 18 (15%)
PIK3CA mutation
Wild-type 353 (82%) 88 (87%) 88 (81%) 91 (83%) 86 (77%)
Mutant 77 (18%) 13 (13%) 20 (19%) 19 (17%) 25 (23%)
Nuclear CTNNB1 (beta-catenin) expression
Negative 238 (53%) 62 (56%) 60 (51%) 59 (54%) 57 (50%)
Positive 213 (47%) 48 (44%) 58 (49%) 51 (46%) 56 (50%)
PTGS2 (cyclooxygenase-2) expression
Negative 179 (38%) 48 (42%) 44 (36%) 45 (38%) 42 (36%)
Positive 291 (62%) 66 (58%) 77 (64%) 72 (62%) 76 (64%)
IRS1 expression
Negative/low 289 (70%) 74 (70%) 83 (76%) 64 (65%) 68 (67%)




Quartile 1 (lowest) 111 (25%) 32 (29%) 28 (25%) 29 (26%) 22 (20%)
Quartile 2 111 (25%) 32 (29%) 18 (16%) 32 (28%) 29 (27%)
Quartile 3 112 (25%) 17 (15%) 37 (33%) 26 (23%) 32 (29%)




Quartile 1 (lowest) 110 (25%) 32 (30%) 28 (25%) 31 (28%) 19 (18%)
(continued)
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Table 2. Colorectal cancer mortality according to postdiagnosis physical activity levels in all cases or in strata of quartiles of T cell densities
Colorectal cancer-specific mortality
HR for a quartile-unit increase of
postdiagnosis physical activity levels
Overall mortality HR for a

















All colorectal cancer cases 470 100 0.77 (0.64 to 0.92) 0.78 (0.64 to 0.95) 275 0.77 (0.69 to 0.86) 0.83 (0.75 to 0.93)
CD3þ cell density
Quartile 1 (lowest) 111 30 0.61 (0.42 to 0.88) 0.56 (0.38 to 0.83) 69 0.75 (0.59 to 0.95) 0.76 (0.62 to 0.93)
Quartile 2 111 23 0.78 (0.53 to 1.15) 0.80 (0.54 to 1.18) 64 0.68 (0.55 to 0.84) 0.72 (0.58 to 0.89)
Quartile 3 112 25 0.75 (0.49 to 1.14) 0.73 (0.47 to 1.11) 68 0.80 (0.63 to 1.02) 0.83 (0.65 to 1.06)
Quartile 4 (highest) 111 15 1.04 (0.73 to 1.49) 1.14 (0.79 to 1.65) 60 0.85 (0.67 to 1.08) 0.96 (0.76 to 1.21)
Pinteraction‡ .004 <.001 .35 .17
CD8þ cell density
Quartile 1 (lowest) 110 34 0.67 (0.48 to 0.92) 0.66 (0.47 to 0.94) 66 0.72 (0.56 to 0.92) 0.78 (0.59 to 1.02)
Quartile 2 109 23 0.84 (0.57 to 1.23) 0.81 (0.56 to 1.18) 65 0.81 (0.65 to 1.00) 0.80 (0.65 to 0.99)
Quartile 3 109 18 0.58 (0.37 to 0.90) 0.56 (0.33 to 0.95) 59 0.62 (0.49 to 0.79) 0.75 (0.59 to 0.95)
Quartile 4 (highest) 109 19 1.03 (0.71 to 1.51) 1.02 (0.67 to 1.56) 64 0.87 (0.69 to 1.10) 0.86 (0.70 to 1.05)
Pinteraction‡ .060 .14 .22 .45
CD45ROþ cell density
Quartile 1 (lowest) 113 33 0.95 (0.69 to 1.31) 0.86 (0.62 to 1.19) 73 0.73 (0.57 to 0.93) 0.77 (0.62 to 0.95)
Quartile 2 113 34 0.70 (0.49 to 1.01) 0.64 (0.44 to 0.95) 69 0.77 (0.60 to 0.97) 0.79 (0.62 to 0.99)
Quartile 3 113 19 0.61 (0.41 to 0.91) 0.65 (0.42 to 1.02) 63 0.74 (0.59 to 0.91) 0.80 (0.65 to 1.00)
Quartile 4 (highest) 112 10 0.87 (0.46 to 1.63) 0.88 (0.44 to 1.72) 60 0.82 (0.66 to 1.03) 0.91 (0.74 to 1.13)
Pinteraction‡ .81 .84 .76 .80
FOXP3þ cell density
Quartile 1 (lowest) 107 32 0.71 (0.50 to 1.00) 0.75 (0.51 to 1.10) 76 0.67 (0.53 to 0.84) 0.74 (0.58 to 0.94)
Quartile 2 106 23 0.69 (0.48 to 0.99) 0.72 (0.48 to 1.08) 67 0.71 (0.58 to 0.87) 0.75 (0.61 to 0.92)
Quartile 3 106 20 0.94 (0.62 to 1.44) 1.02 (0.68 to 1.51) 56 0.98 (0.75 to 1.27) 1.06 (0.85 to 1.33)
Quartile 4 (highest) 107 13 0.66 (0.42 to 1.03) 0.64 (0.40 to 1.03) 49 0.73 (0.56 to 0.94) 0.77 (0.61 to 0.98)
Pinteraction‡ .46 .33 .73 .31
*IPW was applied to reduce a bias due to the availability of questionnaire data after cancer diagnosis (see Statistical Analysis subsection for details). CI ¼ confidence in-
terval; HR ¼ hazard ratio; IPW ¼ inverse probability weighting.
†The multivariable sex-stratified IPW-adjusted Cox regression model initially included age, year of diagnosis, family history of colorectal cancer, body mass index, pre-
diagnosis physical activity, tumor location, tumor differentiation, disease stage, microsatellite instability, CpG island methylator phenotype, long interspersed nucleo-
tide element-1 methylation level, KRAS mutation, BRAF mutation, PIK3CA mutation, nuclear CTNNB1 (beta-catenin) expression, PTGS2 (cyclooxygenase-2) expression,
and IRS1 expression. A backward elimination with a threshold of P equal to .05 was used to select variables for the final models. The variables that remained in the final
models for analyses stratified by CD3þ cell density are described in Appendix Table A2.
‡Pinteraction was calculated using the Wald test for the cross-product of postdiagnosis physical activity levels (the median value of each decile category) and each T cell
subset (the median value of each decile category) in the sex-stratified IPW-adjusted Cox regression model.
Table 1. (continued)
Postdiagnosis physical activity levels
Quartile 1 Quartile 2 Quartile 3 Quartile 4
All cases (Lowest) (Highest)
Characteristic* (n ¼ 470) (n ¼ 114) (n ¼ 121) (n ¼ 117) (n ¼ 118)
Quartile 2 109 (25%) 31 (29%) 22 (20%) 29 (26%) 27 (25%)
Quartile 3 109 (25%) 20 (19%) 27 (24%) 28 (25%) 34 (32%)




Quartile 1 (lowest) 113 (25%) 28 (26%) 27 (23%) 35 (31%) 23 (21%)
Quartile 2 113 (25%) 32 (29%) 33 (28%) 24 (21%) 24 (21%)
Quartile 3 113 (25%) 27 (25%) 29 (25%) 26 (23%) 31 (28%)




Quartile 1 (lowest) 107 (25%) 31 (30%) 27 (24%) 24 (24%) 25 (24%)
Quartile 2 106 (25%) 27 (26%) 39 (34%) 18 (18%) 22 (21%)
Quartile 3 106 (25%) 22 (21%) 24 (21%) 25 (25%) 35 (33%)
Quartile 4 (highest) 107 (25%) 24 (23%) 24 (21%) 35 (34%) 24 (23%)
*Percentage (%) indicates the proportion of cases with a specific clinical, pathological, or molecular characteristic of colorectal cancer cases in all cases or in strata of quar-
tiles of postdiagnosis physical activity levels. AJCC ¼ American Joint Committee on Cancer; CIMP ¼ CpG island methylator phenotype; HPFS ¼ Health Professionals Follow-
up Study; LINE-1¼ long interspersed nucleotide element-1; METS¼metabolic equivalent task score; MSI¼microsatellite instability; NHS¼ Nurses’ Health Study.








niversity in St. Louis user on 15 N
ovem
ber 2019
Our previous studies have suggested that the association of
postdiagnosis physical activity levels with colorectal cancer sur-
vival might differ by nuclear CTNNB1 (42), PTGS2 (39), or IRS1 ex-
pression status (40). Therefore, we performed secondary
analyses stratified jointly by CD3þ cell density with nuclear
CTNNB1, PTGS2, or IRS1 expression status (Table 5). Although
statistical power was limited, there appeared to be a differential
prognostic association by CD3þ cell density across nuclear
CTNNB1 expression status and in PTGS2-positive or IRS1-nega-
tive cases.
In our exploratory analysis, there were no statistically signif-
icant interactions between postdiagnosis physical activity levels
and any of the lymphocytic reaction patterns examined
(Supplementary Table 5, available online).
Discussion
Using two large prospective cohort studies, we tested the hy-
pothesis that the association of postdiagnosis physical activity
levels with colorectal cancer survival might differ by levels of
tumor-infiltrating T cell subsets (CD3þ cells, CD8þ cells,
CD45ROþ cells, or FOXP3þ cells). We found a stronger prognostic
association of postdiagnosis physical activity levels for colorec-
tal cancer accompanied by lower levels of CD3þ pan-T cells than
for cancer accompanied by higher levels of CD3þ cells. Our
results support an interactive effect of physical activity and im-
mune status in the regulation of colorectal cancer progression.
A future study is warranted to examine how the association be-
tween physical activity levels and colorectal cancer incidence
may differ by tumor-infiltrating T cells.
Figure 1. Inverse probability weighting-adjusted Kaplan-Meier curves of colorectal cancer-specific survival and overall survival according to tertiles of postdiagnosis
physical activity levels (<4.5 vs 4.5 to 17.6 vs 17.7 METS-h/wk) in strata of CD3þ cell density. The P values were calculated using the weighted log-rank test (two-sided).
A and B), CD3þ cell-low patients; C and D), CD3þ cell-high patients. METS ¼metabolic equivalent task score.
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Cancer immunotherapies such as immune checkpoint inhib-
itors have shown considerable promise with durable response
(8,10). In colorectal carcinomas, clinical benefits from blockade
therapies targeting the CD274 (PD-L1)-PDCD1 (PD-1) axis have
shown to be greater for MSI-high tumors that are characterized
by higher levels of mutation load and immunogenic neoanti-
gens (9). However, a subset of MSI-high colorectal cancer
responds poorly to immunotherapies. Intensity of the potential
Table 3. Colorectal cancer mortality according to postdiagnosis physical activity levels in all cases or in strata of quartiles of CD3þ cell density
by sex
Colorectal cancer-specific mortality HR
for a quartile-unit increase of
postdiagnosis physical activity levels
Overall mortality HR


















All colorectal cancer cases 252 55 0.72 (0.55 to 0.93) 0.72 (0.55 to 0.94) 134 0.68 (0.58 to 0.80) 0.68 (0.57 to 0.80)
CD3þ cell density
Quartile 1 (lowest) 56 15 0.49 (0.27 to 0.87) 0.45 (0.25 to 0.82) 27 0.52 (0.34 to 0.80) 0.57 (0.35 to 0.91)
Quartile 2 61 14 0.78 (0.47 to 1.29) 0.86 (0.50 to 1.48) 30 0.56 (0.39 to 0.79) 0.55 (0.39 to 0.77)
Quartile 3 65 15 0.90 (0.55 to 1.48) 0.74 (0.44 to 1.25) 40 0.92 (0.69 to 1.22) 0.86 (0.65 to 1.15)
Quartile 4 (highest) 53 6 0.55 (0.38 to 0.80) 0.66 (0.44 to 1.00) 29 0.67 (0.50 to 0.91) 0.74 (0.53 to 1.02)
Pinteraction‡ .071 .11 .60 .37
Male
All colorectal cancer cases 218 45 0.83 (0.65 to 1.07) 0.69 (0.50 to 0.96) 141 0.87 (0.75 to 1.01) 0.98 (0.85 to 1.13)
CD3þ cell density
Quartile 1 (lowest) 55 15 0.73 (0.46 to 1.15) 0.64 (0.39 to 1.05) 42 0.90 (0.70 to 1.15) 0.93 (0.74 to 1.17)
Quartile 2 50 9 0.77 (0.43 to 1.39) 0.60 (0.32 to 1.13) 34 0.79 (0.62 to 1.01) 0.90 (0.70 to 1.15)
Quartile 3 47 10 0.50 (0.23 to 1.09) 0.55 (0.26 to 1.20) 28 0.63 (0.41 to 0.99) 0.82 (0.53 to 1.26)
Quartile 4 (highest) 58 9 1.58 (0.98 to 2.55) 1.55 (0.86 to 2.80) 31 1.08 (0.76 to 1.54) 1.18 (0.84 to 1.65)
Pinteraction‡ .001 <.001 .25 .27
*IPW was applied to reduce a bias due to the availability of questionnaire data after cancer diagnosis (see “Statistical Analysis” subsection for details). CI ¼ confidence
interval; HR ¼ hazard ratio; IPW ¼ inverse probability weighting.
†The multivariable IPW-adjusted Cox regression model initially included age, year of diagnosis, family history of colorectal cancer, body mass index, prediagnosis
physical activity, tumor location, tumor differentiation, disease stage, microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide ele-
ment-1 methylation level, KRAS mutation, BRAF mutation, PIK3CA mutation, nuclear CTNNB1 (beta-catenin) expression, PTGS2 (cyclooxygenase-2) expression, and
IRS1 expression. A backward elimination with a threshold of P equal to .05 was used to select variables for the final models.
‡Pinteraction was calculated using the Wald test for the cross-product of postdiagnosis physical activity levels (the median value of each decile category) and each T cell
subset (the median value of each decile category) in the IPW-adjusted Cox regression model.
Table 4. Colorectal cancer mortality according to tertiles (<4.5, 4.5 to 17.6, and 17.7 METS-h/wk) of postdiagnosis physical activity levels in
strata of CD3þ cell density


















<4.5 METS-h/wk 84 29 1 (referent) 1 (referent) 59 1 (referent) 1 (referent)
4.5 to 17.6 METS-h/wk 66 11 0.42 (0.21 to 0.84) 0.37 (0.18 to 0.77) 34 0.53 (0.34 to 0.81) 0.54 (0.35 to 0.84)
17.7 METS-h/wk 72 13 0.44 (0.23 to 0.84) 0.33 (0.16 to 0.67) 40 0.53 (0.35 to 0.79) 0.53 (0.35 to 0.79)
CD3þ cell-high‡
Postdiagnosis physical activity
<4.5 METS-h/wk 62 13 1 (referent) 1 (referent) 43 1 (referent) 1 (referent)
4.5 to 17.6 METS-h/wk 86 13 0.62 (0.29 to 1.34) 0.58 (0.27 to 1.24) 43 0.58 (0.38 to 0.88) 0.53 (0.35 to 0.81)
17.7 METS-h/wk 75 14 0.75 (0.36 to 1.57) 0.62 (0.30 to 1.29) 42 0.63 (0.41 to 0.96) 0.72 (0.47 to 1.11)
*IPW was applied to reduce a bias due to the availability of questionnaire data after cancer diagnosis (see “Statistical Analysis” subsection for details). CI ¼ confidence
interval; HR ¼ hazard ratio; IPW ¼ inverse probability weighting; METS ¼metabolic equivalent task score.
†The multivariable sex-stratified IPW-adjusted Cox regression model initially included age, year of diagnosis, family history of colorectal cancer, body mass index, pre-
diagnosis physical activity, tumor location, tumor differentiation, disease stage, microsatellite instability, CpG island methylator phenotype, long interspersed nucleo-
tide element-1 methylation level, KRAS mutation, BRAF mutation, PIK3CA mutation, nuclear CTNNB1 (beta-catenin) expression, PTGS2 (cyclooxygenase-2) expression,
and IRS1 expression. A backward elimination with a threshold of P equal to .05 was used to select variables for the final models.
‡CD3þ cell density was categorized as low vs high by the median value.
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anti-tumor immune response is also a major determinant of
the response to immunotherapies in colorectal cancer, which is
affected by multiple endogenous and exogenous factors, includ-
ing the gut microbiota (53–55). In this setting, there is an in-
creasing need for integrative analyses of lifestyle factors, tumor
features, and host immunity (6). A better understanding of the
tumor-immune microenvironment would help us to optimize
preventive and treatment strategies through immune
modulation.
Evidence indicates the role of energy balance in carcinogene-
sis (56), and every tumor differs from other tumors (57). In the
current study, we found a differential prognostic association of
postdiagnosis physical activity levels by CD3þ cell density in co-
lorectal carcinoma tissue. None of the more specific subsets of
T cells statistically significantly modified the prognostic associ-
ation of physical activity. This may indicate that, collectively,
the density of pan-T cells (but not specific types of T cells) may
indeed modify the prognostic effect of physical activity or that
the measurements of the other specific markers of T cells may
need further refinements. In addition, the density of CD3þ pan-
T cells alone may be a potentially useful biomarker to identify
the subpopulation that benefits more from postdiagnosis physi-
cal activity. To our knowledge, this is the first exploratory analy-
sis on the interaction between postdiagnosis physical activity
and immune response for colorectal cancer mortality.
Therefore, our findings need to be validated in independent
cohorts. Studies indicate that exercise can alter the number and
function of circulating immune cells, including CD3þ cells, CD4þ
cells, CD8þ cells, macrophages, and natural killer cells in
healthy populations (29). Studies suggest that higher physical
activity may increase plasma levels of ADIPOQ (adiponectin)
(58–60). ADIPOQ can suppress inflammatory changes in the tu-
mor microenvironment (61,62). Furthermore, higher levels of IL6
released from skeletal muscle during exercise may increase lev-
els of cytokines (eg, IL1R1 and IL10) and cortisol, both of which
exert anti-inflammatory properties (29,63–65). Preclinical stud-
ies suggest that exercise may increase circulating lymphocytes,
promote the infiltration of natural killer cells to tumors, and in-
crease apoptosis of cancer cells (29–31). In mouse models for co-
lorectal cancer, exercise was associated with higher expression
of cytotoxic T cell marker genes in intestinal mucosal tissue
(32). Our population-based data support these mechanistic data,
providing evidence for the immunomodulatory effects of physi-
cal activity in the regulation of colorectal cancer progression in
humans. In the present study, there appeared to be no dose-
response relationship between postdiagnosis physical activity
levels and patient survival in CD3þ cell-low tumors. This may
suggest a possibility of a threshold effect of physical activity for
its immunomodulatory anti-tumor influence. However, we
have been cautious in interpreting an individual HR estimate
comparing each category of physical activity (to the referent
category) in each stratum of patients according to T cell
Table 5. Colorectal cancer mortality according to postdiagnosis physical activity levels in strata of combined CD3þ cell density and nuclear
CTNNB1 (beta-catenin) expression, PTGS2 (cyclooxygenase-2) expression, or IRS1 expression status
Colorectal cancer-specific mortality
HR for a quartile-unit increase
of postdiagnosis physical activity levels
Overall mortality HR for a
quartile-unit increase of
















Nuclear CTNNB1 (beta-catenin) expression
Negative
CD3þ cell-low‡ 109 25 0.60 (0.39 to 0.91) 0.57 (0.37 to 0.88) 65 0.58 (0.46 to 0.74) 0.61 (0.49 to 0.76)
CD3þ cell-high‡ 117 22 0.82 (0.58 to 1.16) 0.81 (0.57 to 1.14) 67 0.79 (0.63 to 1.00) 0.89 (0.72 to 1.10)
Positive
CD3þ cell-low‡ 106 28 0.76 (0.55 to 1.06) 0.74 (0.52 to 1.05) 66 0.79 (0.64 to 0.98) 0.87 (0.70 to 1.07)
CD3þ cell-high‡ 97 16 0.93 (0.55 to 1.58) 1.03 (0.62 to 1.73) 55 0.91 (0.70 to 1.18) 0.96 (0.75 to 1.24)
PTGS2 (cyclooxygenase-2) expression
Negative
CD3þ cell-low‡ 74 14 0.62 (0.38 to 1.02) 0.60 (0.37 to 0.99) 43 0.71 (0.55 to 0.91) 0.71 (0.54 to 0.94)
CD3þ cell-high‡ 90 14 0.58 (0.36 to 0.96) 0.55 (0.33 to 0.90) 51 0.69 (0.53 to 0.89) 0.78 (0.60 to 1.02)
Positive
CD3þ cell-low‡ 148 39 0.71 (0.52 to 0.96) 0.61 (0.44 to 0.86) 90 0.71 (0.58 to 0.86) 0.74 (0.61 to 0.89)
CD3þ cell-high‡ 133 26 1.11 (0.78 to 1.58) 1.06 (0.73 to 1.55) 77 0.95 (0.77 to 1.18) 1.01 (0.82 to 1.24)
IRS1 expression
Negative/low
CD3þ cell-low‡ 136 38 0.62 (0.44 to 0.86) 0.60 (0.42 to 0.86) 89 0.68 (0.56 to 0.82) 0.71 (0.58 to 0.86)
CD3þ cell-high‡ 144 19 0.82 (0.53 to 1.26) 0.76 (0.49 to 1.19) 79 0.87 (0.71 to 1.08) 0.91 (0.74 to 1.12)
High
CD3þ cell-low‡ 57 7 1.73 (1.03 to 2.90) 1.57 (0.93 to 2.64) 30 0.98 (0.72 to 1.34) 0.93 (0.72 to 1.20)
CD3þ cell-high‡ 62 19 1.01 (0.69 to 1.46) 1.18 (0.82 to 1.69) 40 0.80 (0.61 to 1.07) 0.89 (0.67 to 1.19)
*IPW was applied to reduce a bias due to the availability of questionnaire data after cancer diagnosis (see “Statistical Analysis” subsection for details). CI ¼ confidence
interval; HR ¼ hazard ratio; IPW ¼ inverse probability weighting.
†The multivariable sex-stratified IPW-adjusted Cox regression model initially included age, year of diagnosis, family history of colorectal cancer, body mass index, pre-
diagnosis physical activity, tumor location, tumor differentiation, disease stage, microsatellite instability, CpG island methylator phenotype, long interspersed nucleo-
tide element-1 methylation level, KRAS mutation, BRAF mutation, PIK3CA mutation, nuclear CTNNB1 expression (except for CTNNB1-stratified analyses), PTGS2
expression (except for PTGS2-stratified analyses), and IRS1 expression (except for IRS1-stratified analyses). A backward elimination with a threshold of P equal to .05
was used to select variables for the final models.
‡CD3þ cell density was categorized as low vs high by the median value.
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infiltrates, considering multiple hypothesis testing in such
assessments. Further research is needed to assess potential
dose-response effects of physical activity levels on colorectal
cancer mortality in specific tumor types.
There are limitations in the current study. First, limited data
on cancer treatments are available in our study populations.
However, it was unlikely that treatment strategies were deter-
mined by levels of T cell densities, because attending physicians
did not have access to such information. Second, the differential
availability of questionnaire return for physical activity assess-
ment after colorectal cancer diagnosis might have caused a bias.
Thus, we used the IPW method in all survival analyses to reduce
this potential bias. Third, available data on cancer recurrence
were limited, but given the long follow-up duration of censored
cases, colorectal cancer-specific mortality was considered as a
reasonable surrogate for colorectal cancer-specific outcomes.
Strengths of the present study include the use of a molecular
pathological epidemiology (66–69) database derived from two
large prospective cohort studies, which included data on life-
style factors and tumor molecular and immune characteristics.
This integrated database allowed us to examine the interaction
between postdiagnosis physical activity levels and tumor-
infiltrating T cells while adjusting for a variety of potential con-
founders. In addition, this database enabled us to adjust for
long-term physical activity levels before cancer diagnosis.
Participants were enrolled at a large number of hospitals in di-
verse locations across the United States, which might improve
the generalizability of our findings.
The current study suggests that the association of higher
levels of postdiagnosis physical activity with better prognosis is
stronger for colorectal carcinomas with lower CD3þ cell density
than for carcinomas with higher CD3þ cell density. The present
study provides evidence for a potential interaction between
physical activity and anti-tumor immune response in suppress-
ing colorectal cancer progression. Our findings suggest that the
measurement of immune response based on densities of CD3þ
in tumor tissue at diagnosis may help select patients who can
gain the most benefit from exercise.
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Use of standardized official symbols: We use HUGO (Human
Genome Organisation)-approved official symbols (or root sym-
bols) for genes and gene products, including ADIPOQ, BRAF,
CACNA1G, CD3, CD4, CD8, CD274, CDKN2A, CRABP1, CTNNB1,
FOXP3, IGF2, IL1R1, IL6, IL10, IRS1, KRAS, MLH1, NEUROG1,
PDCD1, PIK3CA, PTGS2, PTPRC, RUNX3, and SOCS1, all of which
are described at www.genenames.org. The official symbols are
italicized to differentiate from nonitalicized colloquial names
that are used along with the official symbols. This format enables
readers to familiarize themselves with the official symbols for
genes and gene products together with common colloquial names.
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